PF-AtlasClinical Trials › NCT07108153

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

SION-719 · Phase 2

Registry ID
NCT07108153
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
SION-719
Sponsor
Sionna Therapeutics Inc.
Start
2025-11-03
Enrollment
16
Locations
13

About this trial

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.

View NCT07108153 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT07108153 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.